|
Ruiz-Nodar JM, Marín F, Sánchez-Payá J, Hurtado JA, Valencia-Martín J, Manzano-Fernández S, Roldán V, Pérez-Andreu V, Sogorb F, Valdés M, Lip GY. Efficacy and safety of drug-eluting stent use in patients with atrial fibrillation. Eur Heart J. 2009 Apr;30(8):932-9. doi: 10.1093/eurheartj/ehp045. Epub 2009 Feb 26. PubMed PMID: 19246502.
AÑO: 2009; IF: 9.8
|
19246502
|
Pérez-Andreu V, Roldán V, González-Conejero R, Hernández-Romero D, Vicente V, Marín F. Implications of pharmacogenetics for oral anticoagulants metabolism. Curr Drug Metab. 2009 Jul;10(6):632-42. PubMed PMID: 19799531.
AÑO: 2009; IF: 3.989
|
|
Pérez-Andreu V, Roldán V, Antón AI, García-Barberá N, Corral J, Vicente V, González-Conejero R. Pharmacogenetic relevance of CYP4F2 V433M polymorphism on acenocoumarol therapy. Blood. 2009 May 14;113(20):4977-9. doi: 10.1182/blood-2008-09-176222. Epub 2009 Mar 6. PubMed PMID: 19270263.
AÑO: 2009; IF: 10.555
|
|
Roldán V, Ordoñez A, Marín F, Zorio E, Soria JM, Miñano A, España F, González-Conejero R, Pineda J, Estellés A, Fontcuberta J, Vicente V, Corral J. Antithrombin Cambridge II (A384S) supports a role for antithrombin deficiency in arterial thrombosis. Thromb Haemost. 2009 Mar;101(3):483-6. PubMed PMID: 19277409.
AÑO: 2009; IF: 4.451
|
|
Climent V, Marín F, Mainar L, Roldán V, García A, Martínez JG, Lip GY. Influence of electrical cardioversion on inflammation and indexes of structural remodeling, in persistent atrial fibrillation. Int J Cardiol. 2009 Feb 20;132(2):227-32. doi: 10.1016/j.ijcard.2007.11.044. Epub 2008 Jan 30. PubMed PMID: 18234374.
AÑO: 2009; IF: 3.469
|